IP Library Granted Patent US 10,123,959
Granted Patent B2
US 10,123,959 · App. 15/173,092 · Granted Nov 13, 2018

Methods for treating cellulite

Inventors: Marie A. Badalamente (Mt. Sinai, NY); Alexander B. Dagum (Stony Brook, NY)
Assignee: The Research Foundation for The State University of New York
A61K8/66A61K38/4886A61Q19/06A61K2800/30A61K2800/91
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,123,959
App. No.
15/173,092
Granted
Nov 13, 2018
Kind
B2
Abstract

The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective amount of purified collagenase to the collagenase septa network of cellulite in the skin. The invention also relates to the use of collagenase in the manufacture of a medicament to treat cellulite of the skin.

Claims (13)

1. A method of treating cellulite in a subject in need thereof, comprising the steps of (a) providing a composition consisting essentially of a mixture of purified collagenase I and II in a mass ratio of about 1:1 obtained from Clostridium histolyticum , wherein the mixture has a specific activity of at least 10,000 ABC units per 0.58 mg of collagenase I and II, and (b) injecting the composition to a collagenous septa network of cellulite at a dose of at least 0.18 mg of the mixture of purified collagenase I and II.

2. The method according to claim 1 , wherein the mixture of purified collagenase I and II is injected in an absence of triamcinolone or other corticosteroids.

3. The method according to claim 1 , wherein the dose of purified collagenase I and II is at least 0.25 mg.

4. The method according to claim 1 , wherein the dose of purified collagenase I and II is at least 0.36 mg.

5. The method according to claim 1 , wherein the dose of purified collagenase I and II is at least 0.58 mg.

6. The method according to claim 1 , wherein the composition further consists essentially of a pharmaceutically acceptable carrier.

7. The method according to claim 1 , wherein the mixture of purified collagenase I and II is injected at multiple sites.

8. The method according to claim 1 , wherein the injection is delivered in the area of cellulite, characterized by skin dimpling.

9. The method according to claim 1 , wherein the subject is a human patient.

10. The method according to claim 1 , wherein the treatment is repeated after about four to six weeks.

11. The method according to claim 1 , wherein the composition is administered to a population of human subjects and after one month of receiving at least one administration of the mixture of purified collagenase I and II, at least 89% of the subjects achieve a significant visual reduction in the appearance of cellulite quantified by visual inspection by quadrant in comparison to baseline.

12. The method according to claim 1 , wherein the dose of purified collagenase I and II is at least 0.55 mg.

13. The method according to claim 1 , wherein the dose of purified collagenase I and II is at least 5.48 mg.

Assignments (1)
CHANGE OF NAME Recorded Aug 15, 2016
From: THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 039683/0230 →
Continuity (3)
Continuation 11703269 · Feb 7, 2007
Provisional Application 60775690 · Feb 22, 2006
Related Publication 20160279046A1 · Sep 29, 2016
Cited By (4)
US 12,263,209 US 12,403,081 US 12,448,615 US 12,644,108